Central Alerting System
View Alert

Originator: CMO Messaging

From: CMO Messaging

Issue date: 09-Jun-2020 14:57:34

This alert has been issued to:
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • NHS Trusts (England) - Chief Executive

  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Regional Offices
  • Special Health Authorities
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health

Action category: Important information for immediate action

Title: Second update - Early Access to Medicines Scheme for Remdesivir in the treatment of COVID-19. Implementation of the scheme and management of supply.

Broadcast content: This is the second update we have issued following the original alert of 26 May and the first update on 03 June.

Given current positive medicine supply levels further (restrictive) access criteria beyond those described in the EAMS scientific opinion have now been removed. The access criteria may be further updated as required, for example as further evidence emerges, to reflect developing clinical experience and knowledge of demand and / or if medicine supply varies.

Further information can be found in the attached alert.

Additional information: This alert does not need to be cascaded to Primary Care.

Alert reference: CEM/CMO/2020/025(U2)


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency